Acute myeloid leukemia

New treatments for acute myeloid leukemia: how much has changed?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Martinez-Cuadrón D, Serrano L, Gil C, Tormo M, Martínez-Sánchez P, Pérez-Simón J, et al. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing? Leukemia. e-published 19 October 2020

  2. 2.

    Wei AH, DiNardo CD. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135:85–96.

    Article  Google Scholar 

  3. 3.

    DiNardo CD, Jonas BA, Pullarkat V, Thirman MV, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29.

    CAS  Article  Google Scholar 

  4. 4.

    Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax + LDAC for newly-diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized, placebo-controlled trial. Blood. 2020;135:2137–45.

    CAS  Article  Google Scholar 

  5. 5.

    Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33:379–89.

    CAS  Article  Google Scholar 

  6. 6.

    Estey E, Othus M, Lee SJ, Appelbaum FR, Gale RP. New drug approvals in acute myeloid leuekmia: what’s the best endpoint? Leukemia. 2016;30:521–5.

    CAS  Article  Google Scholar 

  7. 7.

    Estey E, Karp JP, Othus M, Emadi A, Gale RP. Recent drug approvals for newly-diagnosed acute myeloid leukemia: gifts or a Trojan horse? Leukemia. 2020;34:671–81.

    Article  Google Scholar 

  8. 8.

    Amrhein V, Greenland S, McShane B. Retire statistical significance. Nature. 2019;367:305–7.

    Article  Google Scholar 

  9. 9.

    Gale RP, Hochhaus A, Zhang MJ. What is the (p-) value of the P-value? Leukemia. 2016;30:1965–7.

    CAS  Article  Google Scholar 

  10. 10.

    Estey E, Gale RP. How good are we at predicting the fate of someone with acute myeloid leukaemia? Leukemia. 2017;31:1255–8.

    CAS  Article  Google Scholar 

  11. 11.

    Livingston E. Success of antibiotic therapy vs laparoscopic appendectomy for uncomplicated appendicitis in children; a matter of perspective. JAMA. 2020;324:594.

    Article  Google Scholar 

  12. 12.

    Bories P, Lamy S, Simand C, Bertoli S, Delpierre C, Malak S, et al. Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey. Haematologica. 2018;103:2040–8.

    Article  Google Scholar 

  13. 13.

    Schiffer CA. An important gap in informed consent documents for oncology clinical trials: lack of quantitative data about expected treatment outcomes. JAMA Oncol. 2019;5:1399–400.

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Elihu Estey.

Ethics declarations

Conflict of interest

The author declares that he has no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Estey, E. New treatments for acute myeloid leukemia: how much has changed?. Leukemia (2020).

Download citation